Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novo Nordisk to offer...

    Novo Nordisk to offer free insulin to US patients

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-01-04T09:30:20+05:30  |  Updated On 4 Jan 2020 9:30 AM IST

    Novo Nordisk said in September U.S. patients can buy three vials or two packs of pens of its analogue insulins for $99, following similar moves by rivals Sanofi SA and Eli Lilly and Co.


    New Delhi: Novo Nordisk said on Thursday it would offer free, one-time supply of insulin to people in immediate need and at risk of rationing the medication, the rising price of which has attracted fierce criticism from lawmakers and regulators.


    Novo said patients with prescription can get a free, one-time supply of up to three vials or two packs of pens of its insulin, after which they should find a longer-term solution from its other affordability offerings.


    The drugmaker said in September U.S. patients can buy three vials or two packs of pens of its analogue insulins for $99, following similar moves by rivals Sanofi SA and Eli Lilly and Co.


    The cost of insulin for treating type 1 diabetes in the United States had nearly doubled from 2012 to 2016, leading some patients to put their health at risk by rationing the medication.


    Read Also: Novo Nordisk names Vikrant Shrotriya as Managing Director for India business


    Last year, following heavy criticism over the prices, Eli Lilly started selling a half-price version of its Humalog insulin and Sanofi said it would cut the cost of its insulin products to $99 per month for some patients.


    Novo on Thursday also announced the launch of cheaper versions of its heavily prescribed insulin drug, Novolog.


    Read Also: Novo Nordisk wins USFDA nod for oral diabetes drug Rybelsus

    diabetesEli Lillyfree insulinHumalogNovo NordiskNovoLogpharmapharma companypharma newsSanofitype 1 diabetesUS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok